Physician profile
Kr Byju
NPI 1649267972
$9,989.59
in general payments reported to CMS, 2019-2025
45 companies · $956 in 2025
The $956 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,303 · 2020: $713 · 2021: $1,754 · 2022: $2,017 · 2023: $1,602 · 2024: $1,643 · 2025: $956.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,164 · Education: $38.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,163.57 |
| Education | $38.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,605.62 | 2019-2025 | Mavyret, Linzess, Creon |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,147.63 | 2019-2025 | Xifaxan |
| Gilead Sciences, INC. | $860.45 | 2019-2025 | Livdelzi |
| Takeda Pharmaceuticals U.S.A., INC. | $488.29 | 2019-2025 | Entyvio |
| Pfizer INC. | $457.26 | 2020-2025 | |
| Regeneron Healthcare Solutions, INC. | $414.14 | 2022-2025 | Dupixent |
| Genzyme Corporation | $412.27 | 2022-2024 | |
| Intercept Pharmaceuticals, INC. | $383.88 | 2019-2025 | |
| Celgene Corporation | $375.07 | 2021-2024 | Zeposia |
| Madrigal Pharmaceuticals | $342.12 | 2025 | Rezdiffra |
| Evoke Pharma, INC. | $278.34 | 2023-2024 | Gimoti |
| Olympus America INC. | $274.65 | 2019-2024 | Evis X1 Video System Center, Evis Exera III Colonovideoscope |
| Janssen Biotech, INC. | $238.22 | 2019-2025 | Tremfya, Simponi, Simponi Aria |
| Shire North American Group INC | $217.22 | 2019 | |
| Boston Scientific Corporation | $209.32 | 2019-2023 | Cre Pro |
Show all 45 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nestle Healthcare Nutrition INC. | $199.93 | 2020-2023 | |
| Redhill Biopharma INC. | $173.46 | 2021-2023 | Talicia, Aemcolo, Movantik |
| Shionogi INC | $162.54 | 2019-2020 | |
| Mirum Pharmaceuticals, INC. | $144.71 | 2022 | |
| Ardelyx, INC. | $142.59 | 2023-2025 | Ibsrela |
| Merck Sharp & Dohme LLC | $138.16 | 2019-2024 | Dificid |
| Janssen Scientific Affairs, LLC | $137.25 | 2022 | |
| Medtronic, INC. | $136.63 | 2021-2022 | |
| Cvrx, INC. | $128.10 | 2023 | Barostim Neo System |
| Sanofi-Aventis U.S. LLC | $119.35 | 2020 | |
| Fujifilm Healthcare Americas Corporation | $108.44 | 2024 | Fujifilm |
| Ipsen Biopharmaceuticals, INC | $88.55 | 2024-2025 | Iqirvo |
| E.R. Squibb & Sons, L.L.C. | $85.77 | 2022-2024 | Zeposia |
| Ironwood Pharmaceuticals, INC | $64.15 | 2019-2021 | |
| Aimmune Therapeutics, INC. | $60.12 | 2024-2025 | Vowst |
| Neuraxis, INC. | $47.15 | 2025 | |
| Innovation Technologies INC | $43.65 | 2025 | Irrisept |
| Ucb, INC. | $41.41 | 2020-2021 | |
| Vivus LLC | $41.05 | 2022-2023 | Pancreaze |
| Bayer Healthcare Pharmaceuticals INC. | $35.79 | 2022 | |
| Allergan, INC. | $24.50 | 2020 | |
| Astrazeneca Pharmaceuticals LP | $22.26 | 2023 | Andexxa |
| Phathom Pharmaceuticals, INC. | $20.93 | 2024 | Voquezna |
| Lilly USA, LLC | $20.78 | 2024 | Omvoh |
| Lucid Diagnostics INC. | $19.59 | 2023 | |
| Alnylam Pharmaceuticals INC. | $19.24 | 2025 | Givlaari |
| Covidien LP | $18.30 | 2019 | |
| Capsovision, INC. | $15.63 | 2024 | Capsocam Plus |
| Thd America, INC. | $12.90 | 2019 | |
| Cook Medical LLC | $12.18 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kr Byju listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.